QoL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Local tumor control · adults with chordoma
It is very uncertain whether protons changes local control ( compared with photons (very low certainty).
1 finding from 1 review
HR 5.34 [0.66, 43.43]
39 participants
Very low
Mortality ( · adults with chordoma
It is very uncertain whether protons changes mortality ( compared with photons (very low certainty).
1 finding from 1 review
HR 0.44 [0.13, 1.57]
65 participants
Very low
Recurrence · adults with chordoma
It is very uncertain whether protons changes recurrence ( compared with photons (very low certainty).
1 finding from 1 review
HR 0.34 [0.1, 1.17]
81 participants
Very low
Treatment‐related toxicity · adults with chordoma
It is very uncertain whether protons changes treatment‐related toxicity compared with photons (very low certainty).
1 finding from 1 review
Intervention not reported
MSP compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Other techniques (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PSQ compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PSQ compared with MSP · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Variants of PSQ · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
qMSP (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Bead array (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PCR‐mRNA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
MS‐MLPA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PCR‐HRM (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review